Lenalidomide, a widely used immunomodulatory drug for multiple myeloma, has been associated with an increased risk of developing secondary cancers, including skin cancer. According to my knowledge base:

- Increased Risk: People treated with lenalidomide can be more than twice as likely to develop a second cancer compared Show Full Answer

Lenalidomide, a widely used immunomodulatory drug for multiple myeloma, has been associated with an increased risk of developing secondary cancers, including skin cancer. According to my knowledge base:

- Increased Risk: People treated with lenalidomide can be more than twice as likely to develop a second cancer compared to those who did not receive the treatment.
- Incidence Rates: Despite this relative risk, the overall chance of developing a second cancer due to lenalidomide treatment remains low, with incidence rates ranging from 1.5% to 7.4%.

For more detailed information, you can refer to the source: [Second Cancers and Myeloma: Understanding the Connection](https://www.mymyelomateam.com/resources/second-...).

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Second Cancers and Myeloma: Understanding the Connection | MyMyelomaTeam

Rashes and Skin Changes With Myeloma | MyMyelomaTeam